201 related articles for article (PubMed ID: 27720342)
41. The essential role of pharmacists facilitating vaccination in older adults: the case of Herpes Zoster.
Tak CR; Marciniak MW; Savage A; Ozawa S
Hum Vaccin Immunother; 2020; 16(1):70-75. PubMed ID: 31369322
[TBL] [Abstract][Full Text] [Related]
42. Vaccination Coverage Among Adults With Diagnosed Diabetes: United States, 2015.
Villarroel MA; Vahratian A
NCHS Data Brief; 2016 Dec; (265):1-8. PubMed ID: 27930282
[TBL] [Abstract][Full Text] [Related]
43. Vaccines for preventing herpes zoster in older adults.
Gagliardi AM; Andriolo BN; Torloni MR; Soares BG; de Oliveira Gomes J; Andriolo RB; Canteiro Cruz E
Cochrane Database Syst Rev; 2019 Nov; 2019(11):. PubMed ID: 31696946
[TBL] [Abstract][Full Text] [Related]
44. Identifying optimal vaccination scenarios to reduce varicella zoster virus transmission and reactivation.
Bakker KM; Eisenberg MC; Woods RJ; Martinez ME
BMC Med; 2022 Oct; 20(1):387. PubMed ID: 36209074
[TBL] [Abstract][Full Text] [Related]
45. Cost Effectiveness of a Shingles Vaccine Booster for Currently Vaccinated Adults in the U.S.
Le P; Rothberg MB
Am J Prev Med; 2017 Dec; 53(6):829-836. PubMed ID: 29153126
[TBL] [Abstract][Full Text] [Related]
46. Willingness to pay for a QALY based on community member and patient preferences for temporary health states associated with herpes zoster.
Lieu TA; Ray GT; Ortega-Sanchez IR; Kleinman K; Rusinak D; Prosser LA
Pharmacoeconomics; 2009; 27(12):1005-16. PubMed ID: 19908925
[TBL] [Abstract][Full Text] [Related]
47. Early impact of the Australian national shingles vaccination program with the herpes zoster live attenuated vaccine.
Litt J; Booy R; Bourke D; Dwyer DE; Leeb A; McCloud P; Stein AN; Woodward M; Cunningham AL
Hum Vaccin Immunother; 2020 Dec; 16(12):3081-3089. PubMed ID: 32420793
[TBL] [Abstract][Full Text] [Related]
48. Influenza vaccination among adults with asthma findings from the 2007 BRFSS survey.
Lu PJ; Euler GL; Callahan DB
Am J Prev Med; 2009 Aug; 37(2):109-15. PubMed ID: 19589448
[TBL] [Abstract][Full Text] [Related]
49. Long-Term Effectiveness of the Live Zoster Vaccine in Preventing Shingles: A Cohort Study.
Baxter R; Bartlett J; Fireman B; Marks M; Hansen J; Lewis E; Aukes L; Chen Y; Klein NP; Saddier P
Am J Epidemiol; 2018 Jan; 187(1):161-169. PubMed ID: 29309521
[TBL] [Abstract][Full Text] [Related]
50. Herpes zoster vaccine awareness among people ≥ 50 years of age and its implications on immunization.
Javed S; Javed F; Mays RM; Tyring SK
Dermatol Online J; 2012 Aug; 18(8):2. PubMed ID: 22948052
[TBL] [Abstract][Full Text] [Related]
51. H1N1 and seasonal influenza vaccination of U.S. healthcare personnel, 2010.
Lu PJ; Ding H; Black CL
Am J Prev Med; 2012 Sep; 43(3):282-92. PubMed ID: 22898121
[TBL] [Abstract][Full Text] [Related]
52. Shingles (herpes zoster) vaccine (zostavax(®)): a review of its use in the prevention of herpes zoster and postherpetic neuralgia in adults aged ≥50 years.
Keating GM
Drugs; 2013 Jul; 73(11):1227-44. PubMed ID: 23839657
[TBL] [Abstract][Full Text] [Related]
53. Herpes zoster vaccine effectiveness and manifestations of herpes zoster and associated pain by vaccination status.
Marin M; Yawn BP; Hales CM; Wollan PC; Bialek SR; Zhang J; Kurland MJ; Harpaz R
Hum Vaccin Immunother; 2015; 11(5):1157-64. PubMed ID: 25806911
[TBL] [Abstract][Full Text] [Related]
54. Cost-effectiveness of a vaccine to prevent herpes zoster and postherpetic neuralgia in older adults.
Hornberger J; Robertus K
Ann Intern Med; 2006 Sep; 145(5):317-25. PubMed ID: 16954357
[TBL] [Abstract][Full Text] [Related]
55. [Shingles vaccine: which recommendations in 2014?].
Vionnet J; Hart K; Spertini F
Rev Med Suisse; 2014 Apr; 10(426):869-72, 874-5. PubMed ID: 24834646
[TBL] [Abstract][Full Text] [Related]
56. Pneumococcal polysaccharide vaccination among adults aged 65 years and older, U.S., 1989-2008.
Lu PJ; Nuorti JP
Am J Prev Med; 2010 Oct; 39(4):287-95. PubMed ID: 20837278
[TBL] [Abstract][Full Text] [Related]
57. Evaluation of the effect of the herpes zoster vaccination programme 3 years after its introduction in England: a population-based study.
Amirthalingam G; Andrews N; Keel P; Mullett D; Correa A; de Lusignan S; Ramsay M
Lancet Public Health; 2018 Feb; 3(2):e82-e90. PubMed ID: 29276017
[TBL] [Abstract][Full Text] [Related]
58. Low Rates of Vaccination for Herpes Zoster in Older People Living With HIV.
Erlandson KM; Streifel A; Novin AR; Hawkins KL; Foster C; Langness J; Bessesen M; Falutz J; Moanna A; Looney D; Johns ST; Nguyen JB; Oxman MN; Levin MJ
AIDS Res Hum Retroviruses; 2018 Jul; 34(7):603-606. PubMed ID: 29661022
[TBL] [Abstract][Full Text] [Related]
59. Zoster vaccine (Zostavax): a review of its use in preventing herpes zoster and postherpetic neuralgia in older adults.
Sanford M; Keating GM
Drugs Aging; 2010 Feb; 27(2):159-76. PubMed ID: 20104941
[TBL] [Abstract][Full Text] [Related]
60. Public health impact model estimating the impact of introducing an adjuvanted recombinant zoster vaccine into the UK universal mass vaccination programme.
van Oorschot DAM; Hunjan M; Bracke B; Lorenc S; Curran D; Starkie-Camejo H
BMJ Open; 2019 May; 9(5):e025553. PubMed ID: 31061027
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
